Apheresis clinical trials

Explore recruiting apheresis clinical trials.

Recruiting apheresis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Apheresis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients with hyperlipoproteinemia(a) and established cardiovascular disease undergoing weekly lipoprotein apheresis in Germany

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single arm, open label extension (OLE), multicenter study to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in patients with cardiovascular disease who have successfully completed the Frontiers Apheresis parent study

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Netherlands, Denmark, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)

Greece, France, Belgium, Germany, Netherlands, Austria +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma – The GENESIS Study

Italy, Spain, Hungary, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (SHASTA-10 STUDY)

Lithuania, Poland, Latvia, Slovakia, Bulgaria, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Apheresis trials by city

Apheresis in Toronto Apheresis in Vancouver Apheresis in Montreal Apheresis in Calgary Apheresis in Edmonton Apheresis in Ottawa Apheresis in Winnipeg Apheresis in Quebec City Apheresis in Hamilton Apheresis in Kitchener Apheresis in London Apheresis in Halifax Apheresis in New York Apheresis in Los Angeles Apheresis in Chicago Apheresis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease